Spark Therapeutics reported a net loss of $47.4 million, or $1.26 per share, in 2018’s third quarter compared with a net loss of $65 million, or $1.90 per share, in the third quarter of 2017, according to a press release.
Total revenue for the quarter was $10.7 million, with sales of Luxturna (voretigene neparvovec-rzyl) comprising $8.9 million of that total and $1.8 million coming from agreements with Pfizer. Revenue totaled $1.9 million in the same quarter a year ago.
Research and development costs decreased from $39.3 million in 2017’s third (Read more...)
Uncategorized